For a period exceeding three decades, Rudolf Stadler served as the chairperson of the prestigious medical institution, the University Clinic for Dermatology at the Johannes Wesling Medical Centre in Minden, University Clinic of the Ruhr University of Bochum, Germany. In his current capacity as the Head of Dermatopathology, he has spearheaded numerous clinical trials and dermato-oncology initiatives. His research is centred on the field of dermato-oncology, with a particular emphasis on cutaneous T-cell and B-cell lymphomas. Furthermore, he conducts randomised controlled trials in CTCL. He had previously served as the chairman of the EORTC CTCL Tumor Group and was instrumental in initiating a functional dermatology shift as former president of the German Dermatological Society in Germany. He has been honoured with several prestigious awards, including the German Skin Cancer Prize, the Oscar-Gans-Preis from the German Society of Dermatology, and the Karl-Herxheimer Medal (2023) from the German Dermatological Society. In addition, he is a pioneering figure in the field of dermato-oncology and the advancement of therapeutic interventions for cutaneous T-cell lymphoma in both Germany and Europe. In addition to his research contributions, he serves on the Board of Directors of the International Society for Cutaneous Lymphomas, where he plays an active role in shaping the society’s strategic direction and fostering international collaboration in the field.
🏥 University Affiliation, City, Country: Head of Dermatopathology, Cutaneous Lymphoma Centre, University Department of Dermatology, Johannes Wesling Medical Cancer Centre, Ruhr University of Bochum, Minden, Germany
🧪 Area of focus in clinical practice and research: Advancement of clinical research in cutaneous lymphoma, treatment of cutaneous T-cell lymphoma (CTCL), and molecular understanding of CTCL.
🔎 Looking forward to in the field of cutaneous lymphomas and at the 6th WCCL: Presentation on epidemiology of cutaneous lymphoma, current classification of cutaneous lymphomas, development of CTCL and B-cell lymphomas, and latest research data on aggressive lymphomas, CD30 lymphoproliferative diseases, biological enigma of lymphomatoid papulosis, biological behavior of large cell anaplastic lymphomas ALK negative, PROCLIPI Project, and new T classification.
💭 What are you passionate about in medicine or recreationally? Passionate about the study of cutaneous lymphoma; recreationally enjoys creating ephemeral artworks and alpine skiing.
🏆 A short story or academic achievement you are proud of: Conducted the first multicentre randomised clinical study of CTCL in the 1990s, combining interferon with phototherapy using PUVA therapy.
🌟 Secret to career success: Profound interest in dermatology, maintaining a line of research, and translating dermatopathology into a framework of pathophysiological thinking.